Mathai Mammen, M.D., Ph.D., is currently in transition to be Global Head of R&D for the Janssen Pharmaceuticals Companies of Johnson & Johnson. Previously, he was Senior Vice President, Cardiovascular diseases, Metabolic diseases, Immunology and Oncology at Merck. Dr. Mammen earlier served Theravance Biopharma as Senior Vice President, Research and Development. Prior to joining Theravance Biopharma, he co-founded Theravance, Inc. in 1996 and held senior management positions from 2008 to 2014, most recently as Senior Vice President, Research and Development. Previously, he served in various positions in both the Medicinal Chemistry Department and the Molecular and Cellular Biology Departments at Theravance, Inc., most recently as Vice President, Molecular and Cellular Biology. Dr. Mammen obtained his M.D. from Harvard Medical School/Massachusetts Institute of Technology, and his Ph.D. in Physical Organic Chemistry from Harvard University's Department of Chemistry working with George Whitesides, Ph.D. Dr. Mammen obtained his Bachelor's Degree in Chemistry from Dalhousie University in Halifax, Nova Scotia.